The activation of AMPK induces the translocation of GLUT4 to the plasma membrane, and several studies have demonstrated that AMPK and its signaling pathway are potential molecular targets in the development of drugs for the treatment of type 2 diabetes and obesity [19]. This evidence concerns the gene SLC2A4 and obesity due to melanocortin 4 receptor deficiency.